← Back to Search

Other

ATH-1020 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Athira Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up samples collected pre-dose on day 1 and predetermined timepoints on day 1, 9, and 10, within 24 hours post-dose.
Awards & highlights

Study Summary

This trial will study the effects of ATH-1020 on healthy young and elderly subjects to see if it is safe and tolerable.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~samples collected pre-dose on day 1 and predetermined timepoints on day 1, 9, and 10, within 24 hours post-dose.
This trial's timeline: 3 weeks for screening, Varies for treatment, and samples collected pre-dose on day 1 and predetermined timepoints on day 1, 9, and 10, within 24 hours post-dose. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Secondary outcome measures
Amount of IMP excreted unchanged in the urine (Ae)
Area under the plasma concentration time curve (AUC)
Half-life (t1/2)
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ATH-1020Experimental Treatment1 Intervention
ATH-1020 in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of ATH-1020. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of ATH-1020 (up to 4 for cohort B5).
Group II: PlaceboPlacebo Group1 Intervention
Placebo in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of Placebo. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ATH-1020
2022
Completed Phase 1
~40

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Biotrial Inc.UNKNOWN
1 Previous Clinical Trials
88 Total Patients Enrolled
Athira PharmaLead Sponsor
6 Previous Clinical Trials
1,209 Total Patients Enrolled
Alturas Analytics, Inc.UNKNOWN
1 Previous Clinical Trials
8 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the scale of enrolment in this trial?

"Affirmative. Per the information hosted on clinicaltrials.gov, this clinical trial is actively enrolling participants as of August 26th 2022 and was posted initially March 30th 2022. 68 patients are needed at one medical site to fill out the study."

Answered by AI

Who meets the qualifications for participating in this research endeavor?

"This clinical trial is looking to recruit 68 individuals aged between 18 and 85 with a healthy demeanour (hs). Other criteria that must be met for admission include: meeting the requirements of Part A (SAD) or Part B (MAD), having a Body Mass Index ranging from 18.0 to 32.0 kg/m2 at screening, minimum weight requirement of 60kgs., overall good health as judged by the investigator, sufficient venous access, and male subjects willing to comply with contraceptive regulations of this study."

Answered by AI

Does this clinical trial permit enrollees who are thirty or more years old?

"Patients aged between 18 and 85 are eligible to apply for this trial. Additionally, the clinicaltrials.gov website provides 50 trials specifically for minors and 372 studies targeting people over 65 years old."

Answered by AI

Can more participants join this experiment?

"Accurate. According to information found on clinicaltrials.gov, this research study is actively searching for suitable individuals beginning March 30th 2022 with the last update being August 26th 2022. 68 patients are needed from a single site."

Answered by AI

Has ATH-1020 been granted approval from the FDA?

"Due to the lack of substantial evidence indicating ATH-1020's efficacy and safety, it received a score of 1 on our scale."

Answered by AI

Who else is applying?

What state do they live in?
Pennsylvania
New Jersey
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
What site did they apply to?
Biotrial, Inc.
Recent research and studies
clinicaltrials.govStudy
Safety, Tolerability, and Pharmacokinetics Study of ATH-1020
2022. "Safety, Tolerability, and Pharmacokinetics Study of ATH-1020". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05169671.
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top